Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment.

Kirchhammer, Nicole; Trefny, Marcel P; Auf der Maur, Priska; Läubli, Heinz; Zippelius, Alfred

Kirchhammer, Nicole; Trefny, Marcel P; Auf der Maur, Priska; Läubli, Heinz; Zippelius, Alfred.

Afiliación

Kirchhammer N; Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel 4031, Switzerland.
Trefny MP; Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel 4031, Switzerland.
Auf der Maur P; Tumor Heterogeneity, Metastasis and Resistance, Department of Biomedicine, University and University Hospital of Basel, Basel 4031, Switzerland.
Läubli H; Cancer Immunotherapy, Department of Biomedicine, University and University Hospital Basel, Basel 4031, Switzerland.
Zippelius A; Medical Oncology, University Hospital Basel, Basel 4031, Switzerland.

Sci Transl Med ; 14(670): eabo3605, 2022 11 09.

Article en En | MEDLINE | ID: mdl-36350989

ABSTRACT

ABSTRACT

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims to give an update on recent developments in immunotherapy for solid tumors and highlights progress in translational research and clinical practice.

Asunto(s)

Neoplasias; Microambiente Tumoral; Humanos; Inmunoterapia; Neoplasias/patología

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google